Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2.
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2.
复制标题
DOI：
10.1016/j.annonc.2020.10.473
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Curigliano G
中科院分区：
文献类型：
--
作者：
Marra A;Generali D;Zagami P;Cervoni V;Gandini S;Venturini S;Morganti S;Passerini R;Orecchia R;Curigliano G
癌症患者发生严重并发症的风险较高，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关疾病[2019冠状病毒病（COVID-19）]的结局较差。几乎所有COVID-19受试者在感染后3周内都会产生抗SARS-CoV-2免疫球蛋白G（IgG）。没有关于癌症患者和COVID-19的血清转换率的数据。我们进行了一项多中心、观察性、前瞻性研究，纳入了（i）经鼻/咽拭子标本实时RT-PCR检测证实为SARS-CoV-2感染的患者和肿瘤学健康专业人员;（ii）临床或放射学怀疑为SARS-CoV-2感染的患者和肿瘤学健康专业人员;和（iii）被认为感染风险高且适合积极治疗和/或大手术的癌症患者。所有入组受试者均使用2019-nCoV IgG/IgM快速检测卡进行检测，该检测卡是一种用于检测SARS-CoV-2 IgG和IgM抗体的定性膜基免疫测定法。该研究的目的是评估确诊或临床疑似COVID-19的癌症患者和肿瘤学医护人员的抗SARS-CoV-2血清转换率。于2020年3月30日至2020年5月11日，166名受试者入组研究。其中，癌症患者61人（36.7%），医务人员105人（63.3%）。总体而言，86名受试者（51.8%）通过鼻咽拭子标本的RT-PCR检测确认了SARS-CoV-2诊断，60名（36.2%）临床疑似COVID-19。从症状发作（对于未经RT-PCR证实的病例）或RT-PCR证实至血清抗体检测的中位时间为17天（四分位距26）。在RT-PCR确诊人群中，IgG阳性率为83.8%。肿瘤患者和医务人员IgG阳性率无显著性差异（87.9%对80.5%; P = 0.39）。我们的数据表明，SARS-CoV-2特异性IgG抗体检测在癌症患者和健康受试者之间没有差异。
Patients with cancer have high risk for severe complications and poor outcome to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease [coronavirus disease 2019 (COVID-19)]. Almost all subjects with COVID-19 develop anti-SARS-CoV-2 immunoglobulin G (IgG) within 3 weeks after infection. No data are available on the seroconversion rates of cancer patients and COVID-19. We conducted a multicenter, observational, prospective study that enrolled (i) patients and oncology health professionals with SARS-CoV-2 infection confirmed by real-time RT-PCR assays on nasal/pharyngeal swab specimens; (ii) patients and oncology health professionals with clinical or radiological suspicious of infection by SARS-CoV-2; and (iii) patients with cancer who are considered at high risk for infection and eligible for active therapy and/or major surgery. All enrolled subjects were tested with the 2019-nCoV IgG/IgM Rapid Test Cassette, which is a qualitative membrane-based immunoassay for the detection of IgG and IgM antibodies to SARS-CoV-2. The aim of the study was to evaluate anti-SARS-CoV-2 seroconversion rate in patients with cancer and oncology health care professionals with confirmed or clinically suspected COVID-19. From 30 March 2020 to 11 May 2020, 166 subjects were enrolled in the study. Among them, cancer patients and health workers were 61 (36.7%) and 105 (63.3%), respectively. Overall, 86 subjects (51.8%) had confirmed SARS-CoV-2 diagnosis by RT-PCR testing on nasopharyngeal swab specimen, and 60 (36.2%) had a clinical suspicious of COVID-19. Median time from symptom onset (for cases not confirmed by RT-PCR) or RT-PCR confirmation to serum antibody test was 17 days (interquartile range 26). In the population with confirmed RT-PCR, 83.8% of cases were IgG positive. No difference in IgG positivity was observed between cancer patients and health workers (87.9% versus 80.5%; P = 0.39). Our data indicate that SARS-CoV-2-specific IgG antibody detection do not differ between cancer patients and healthy subjects.
登录
查看更多内容
影响因子：
12.7
作者：
Li, Zhengtu;Yi, Yongxiang;Ye, Feng
通讯作者：
Ye, Feng
影响因子：
28.2
作者：
Dai, Mengyuan;Liu, Dianbo;Cai, Hongbing
通讯作者：
Cai, Hongbing
影响因子：
5.4
作者：
Rolston KV
通讯作者：
Rolston KV
影响因子：
5
作者：
Meyer B;Drosten C;Müller MA
通讯作者：
Müller MA
影响因子：
82.9
作者：
He, Xi;Lau, Eric H. Y.;Leung, Gabriel M.
通讯作者：
Leung, Gabriel M.